Share Email Print
cover

Proceedings Paper

Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance- corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

Paper Details

Date Published: 9 July 2001
PDF: 7 pages
Proc. SPIE 4257, Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical, (9 July 2001); doi: 10.1117/12.434744
Show Author Affiliations
Paulo R. Bargo, Oregon Medical Laser Ctr./Providence St. Vincent Medical Ctr. and Oregon Graduate Institut (United States)
Steven L. Jacques, Oregon Medical Laser Ctr./Providence St. Vincent Medical Ctr. and Oregon Graduate Institut (United States)


Published in SPIE Proceedings Vol. 4257:
Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical
Donald Dean Duncan; Peter C. Johnson; Donald Dean Duncan; Steven L. Jacques; Peter C. Johnson, Editor(s)

© SPIE. Terms of Use
Back to Top